GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore the potential of cancer prevention through vaccination.

The partnership, through the GSK-Oxford immuno-prevention programme, will focus on translational research, delving into precancer biology to uncover insights into the development of cancer in humans, which could lead to new vaccination approaches.

To back this early research, GSK has committed to invest up to £50m ($62.3m) over at least three years.

The new programme will leverage Oxford's expertise in precancer biology, including the identification and sequencing of neoantigens that could be targeted to prevent cancer progression.

GSK chief scientific officer Tony Wood stated: “We’re pleased to further strengthen our relationship with Oxford University and to combine the deep knowledge of Oxford and GSK scientists.

“By exploring precancer biology and building on GSK’s expertise in the science of the immune system, we aim to generate key insights for people at risk of developing cancer.”

The partnership builds on the existing relationship between both entities, which includes the Institute of Molecular and Computational Medicine established in 2021.

The Institute has made strides in the research and development of new medicines, particularly in neurodegeneration.

In a separate development, the European Medicines Agency (EMA) has accepted GSK’s application for a prefilled syringe presentation of recombinant zoster vaccine, Shingrix, for review, to prevent shingles.

The new presentation claims to simplify administration by eliminating the need to mix a powder antigen with a liquid adjuvant. The submission is supported by data demonstrating comparability between the new prefilled syringe and the current reconstituted vaccine.

The EMA's acceptance of the prefilled syringe follows the European Commission’s (EC) approval of GSK's Jemperli, combined with chemotherapy for the treatment of advanced or recurrent endometrial cancer.